Literature DB >> 2554848

Delayed formation of gallstone after transcatheter arterial embolization for hepatocellular carcinoma. Is elective cholecystectomy advisable during hepatectomy?

K S Jeng1, H J Chiang.   

Abstract

Two hundred twenty-five transcatheter hepatic arterial embolizations (TAEs) were performed on 137 patients with hepatocellular carcinoma (HCC) during a three-year period. The postembolization changes of the gallbladder were studied by regular follow-up with ultrasonography. Twenty-four patients (10.7%) were found to have an acute infarction of the gallbladder within two weeks immediately following chemoembolization. Gallbladder infarction was related to inadequate superselectivity, regurgitation of chemoembolus, or unavoidable anatomic limitations. Four of the 24 patients were found to have delayed formation of gallstones, with the time lapses after TAEs being 2, 2, 3, and 5 months, respectively. One patient underwent surgical reexploration for cholecystectomy 14 months after resection of her HCC because of intractable symptoms and signs of chronic cholecystitis. There are four possible mechanisms of development of gallstones. Cholecystectomy should be performed during the elective hepatectomy for resectable HCC in patients who have received preoperative TAEs.

Entities:  

Mesh:

Year:  1989        PMID: 2554848     DOI: 10.1001/archsurg.1989.01410110077015

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  2 in total

1.  Impact of severe oesophagogastric varices on liver resection for hepatocellular carcinoma in cirrhotic patients.

Authors:  Hsiao-Tien Liu; Shao-Bin Cheng; Cheng-Chung Wu; Hong-Zen Yeh; Chi-Sen Chang; John Wang
Journal:  World J Surg       Date:  2015-02       Impact factor: 3.352

2.  Repeat operation for nodular recurrent hepatocellular carcinoma within the cirrhotic liver remnant: a comparison with transcatheter arterial chemoembolization.

Authors:  K S Jeng; F S Yang; H J Chiang; I Ohta
Journal:  World J Surg       Date:  1992 Nov-Dec       Impact factor: 3.352

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.